Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders

被引:46
作者
Bisogno, Tiziana [1 ]
Di Marzo, Vincenzo [1 ]
机构
[1] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, Naples, Italy
关键词
cannabinoid; receptor; anxiety depression; neuromotor disorders; stress; anandamide; 2-arachidonoylglycerol;
D O I
10.1016/j.phrs.2007.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The activity of the endocannabinoid system, in terms of the levels of the endocannabinoids and of cannabinoid receptors, or of the functional coupling of the latter to a biological response, undergoes to remodelling during pathological conditions. In the CNS, these changes, depending also on the nature of the disorder, can be transient or long-lasting, occur only in those tissues involved in the pathological condition and usually aim at restoring the physiological homeostasis by reducing excitotoxicity, inflammation and neuronal death. However, during chronic disorders, prolonged activation of the enclocannabinoid system might also contribute to the symptoms of the pathology. Whilst acute changes of the tissue levels of the endocannabinoids reflect the "on demand" nature of their biosynthesis and release, and hence are effected mostly through regulation of the biosynthetic enzymes, chronic changes seem to be mostly due to longer-lasting alterations in the expression of anabolic and catabolic enzymes. The possibility of obtaining therapeutic advantage from enclocannabinoid plasticity in neuropsychiatric and neurological disorders is discussed in this review article. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:428 / 442
页数:15
相关论文
共 195 条
  • [31] Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs
    Cupini, LM
    Bari, M
    Battista, N
    Argirò, G
    Finazzi-Agrò, A
    Calabresi, P
    Maccarrone, M
    [J]. CEPHALALGIA, 2006, 26 (03) : 277 - 281
  • [32] Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation
    D'Argenio, G
    Valenti, M
    Scaglione, G
    Cosenza, V
    Sorrentini, I
    Di Marzo, V
    [J]. FASEB JOURNAL, 2006, 20 (01) : 568 - +
  • [33] In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake
    de Lago, E
    Ligresti, A
    Ortar, G
    Morera, E
    Cabranes, A
    Pryce, G
    Bifulco, M
    Baker, D
    Fernandez-Ruiz, J
    Di Marzo, V
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 484 (2-3) : 249 - 257
  • [34] UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
    de Lago, E
    Fernández-Ruiz, J
    Ortega-Gutiérrez, S
    Cabranes, A
    Pryce, G
    Baker, D
    López-Rodríguez, M
    Ramos, JA
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (01) : 7 - 18
  • [35] Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity:: in vivo and in vitro evidence
    de Lago, E
    de Miguel, R
    Lastres-Becker, I
    Ramos, JA
    Fernández-Ruiz, J
    [J]. BRAIN RESEARCH, 2004, 1007 (1-2) : 152 - 159
  • [36] Endocannabinoid signalling in the blood of patients with schizophrenia
    Nicola De Marchi
    Luciano De Petrocellis
    Pierangelo Orlando
    Fabiana Daniele
    Filomena Fezza
    Vincenzo Di Marzo
    [J]. Lipids in Health and Disease, 2 (1)
  • [37] In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission
    Degroot, Aldemar
    Nomikos, George G.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (01) : 62 - 68
  • [38] CB1 receptor antagonism increases hippocampal acetylcholine release:: Site and mechanism of action
    Degroot, Aldemar
    Kofalvi, Attila
    Wade, Mark R.
    Davis, Richard J.
    Rodrigues, Ricardo J.
    Rebola, Nelson
    Cunha, Rodrigo A.
    Nomikos, George G.
    [J]. MOLECULAR PHARMACOLOGY, 2006, 70 (04) : 1236 - 1245
  • [39] Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
    Denovan-Wright, EM
    Robertson, HA
    [J]. NEUROSCIENCE, 2000, 98 (04) : 705 - 713
  • [40] Endocannabinoids block, status epilepticus in cultured hippocampal neurons
    Deshpande, Laxmikant S.
    Blair, Robert E.
    Ziobro, Julie M.
    Sombati, Sompong
    Martin, Billy R.
    DeLorenzo, Robert J.
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 558 (1-3) : 52 - 59